CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") (CTMX)

Q: What does CUSIP 23284F105 represent in this 13F holders report?

CUSIP 23284F105 is the security identifier for CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") used to aggregate holder disclosures.

Q: How many institutions held CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") in Q4 2023?

66 institutional investors reported CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") for Q4 2023. Use the holders table for investor-level position and value details.

CUSIP: 23284F105

Q4 2023 13F Holders as of 31 Dec 2023

Type / Class: Equity / Common Stock, $0.00001 par value per share ("Common Stock")
Shares outstanding: 217,079,600
Total 13F shares: 32,640,376
Share change: +214,352
Total reported value: $50,592,909
Put/Call ratio: 16%
Price per share: $1.55
Number of holders: 66
Value change: +$410,206
Number of buys: 22
Number of sells: 22

Quarterly Holders Quick Answers

What is CUSIP 23284F105?
CUSIP 23284F105 identifies CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2024
Previous quarter: Q3 2023

Recent filing periods for CUSIP 23284F105:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
BVF INC/IL	13F	Company	3%	6,595,801	$8,508,583	—	30 Sep 2023	13F
TANG CAPITAL MANAGEMENT LLC	13F	Company	3%	6,450,000	$8,320,500	—	30 Sep 2023	13F
VANGUARD GROUP INC	13F	Company	2.3%	4,902,943	$6,324,797	—	30 Sep 2023	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	1.2%	2,646,190	$3,412,000	—	30 Sep 2023	13F
Laurion Capital Management LP	13F	Company	0.55%	1,188,225	$1,532,810	—	30 Sep 2023	13F
BlackRock Finance, Inc.	13F	Company	0.52%	1,139,636	$1,470,130	—	30 Sep 2023	13F
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	0.48%	1,052,105	$1,357,215	—	30 Sep 2023	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.43%	930,100	$1,200,000	—	30 Sep 2023	13F
Bronte Capital Management Pty Ltd.	13F	Company	0.43%	925,245	$1,193,566	—	30 Sep 2023	13F
FMR LLC	13F	Company	0.33%	707,968	$913,278	—	30 Sep 2023	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.32%	698,906	$901,589	—	30 Sep 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.31%	676,343	$872,707	—	30 Sep 2023	13F
Assenagon Asset Management S.A.	13F	Company	0.2%	425,921	$549,438	—	30 Sep 2023	13F
MARSHALL WACE, LLP	13F	Company	0.17%	377,593	$487,095	—	30 Sep 2023	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.17%	372,124	$480,040	—	30 Sep 2023	13F
Formidable Asset Management, LLC	13F	Company	0.15%	318,111	$410,363	—	30 Sep 2023	13F
Tidal Investments LLC	13F	Company	0.15%	318,111	$410,363	—	30 Sep 2023	13F
STATE STREET CORP	13F	Company	0.12%	267,476	$345,044	—	30 Sep 2023	13F
Bank of New York Mellon Corp	13F	Company	0.12%	266,836	$344,218	—	30 Sep 2023	13F
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	13F	Company	0.12%	259,965	$335,355	—	30 Sep 2023	13F
Clearline Capital LP	13F	Company	0.09%	196,583	$253,592	—	30 Sep 2023	13F
Squarepoint Ops LLC	13F	Company	0.08%	173,625	$223,976	—	30 Sep 2023	13F
Connor, Clark & Lunn Investment Management Ltd.	13F	Company	0.07%	145,934	$188,255	—	30 Sep 2023	13F
NORTHERN TRUST CORP	13F	Company	0.06%	119,919	$154,695	—	30 Sep 2023	13F
Congress Park Capital LLC	13F	Company	0.05%	112,450	$145,061	—	30 Sep 2023	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.05%	107,900	$139,191	—	30 Sep 2023	13F
LPL Financial LLC	13F	Company	0.05%	105,392	$135,956	—	30 Sep 2023	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.04%	88,570	$114,255	—	30 Sep 2023	13F
CORNERCAP INVESTMENT COUNSEL INC	13F	Company	0.04%	81,352	$104,944	—	30 Sep 2023	13F
D. E. Shaw & Co., Inc.	13F	Company	0.03%	73,494	$94,807	—	30 Sep 2023	13F
Private Advisor Group, LLC	13F	Company	0.03%	73,179	$94,401	—	30 Sep 2023	13F
MORGAN STANLEY	13F	Company	0.03%	63,660	$82,121	—	30 Sep 2023	13F
Amy C. Peterson	3/4/5	EVP, Chief Development Officer	— class O/S missing	58,433	$80,678	—	16 Mar 2023	3/4/5
CITADEL ADVISORS LLC	13F	Company	0.03%	60,166	$77,614	—	30 Sep 2023	13F
COMMONWEALTH EQUITY SERVICES, LLC	13F	Company	0.02%	53,243	$69,000	—	30 Sep 2023	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.02%	50,092	$64,619	—	30 Sep 2023	13F
Forefront Analytics, LLC	13F	Company	0.02%	49,421	$63,754	—	30 Sep 2023	13F
Russell Investments Group, Ltd.	13F	Company	0.02%	45,626	$58,856	—	30 Sep 2023	13F
TUDOR INVESTMENT CORP ET AL	13F	Company	0.02%	44,730	$57,702	—	30 Sep 2023	13F
Carlos Campoy	3/4/5	Chief Financial Officer	— class O/S missing	38,224	$52,776	—	16 Mar 2023	3/4/5
Alison L. Hannah	3/4/5	Chief Medical Officer	— class O/S missing	31,898	$44,042	—	19 Jul 2022	3/4/5
FRANKLIN RESOURCES INC	13F	Company	0.01%	26,838	$34,621	—	30 Sep 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.01%	25,565	$32,978	—	30 Sep 2023	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.01%	24,817	$32,014	—	30 Sep 2023	13F
Invesco Ltd.	13F	Company	0.01%	22,071	$28,472	—	30 Sep 2023	13F
UBS Group AG	13F	Company	0.01%	18,703	$24,127	—	30 Sep 2023	13F
WestHill Financial Advisors, Inc.	13F	Company	0.01%	17,082	$22,036	—	30 Sep 2023	13F
PRUDENTIAL FINANCIAL INC	13F	Company	0.01%	16,300	$21,027	—	30 Sep 2023	13F
MACKENZIE FINANCIAL CORP	13F	Company	0.01%	15,637	$19,390	—	30 Sep 2023	13F
Ground Swell Capital, LLC	13F	Company	0.01%	10,966	$14,146	—	30 Sep 2023	13F

Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") (CTMX) as of Q4 2023

As of 31 Dec 2023, CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") (CTMX) was held by 66 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 32,640,376 shares. The largest 10 holders included BVF INC/IL, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., Laurion Capital Management LP, Bronte Capital Management Pty Ltd., MILLENNIUM MANAGEMENT LLC, and JACOBS LEVY EQUITY MANAGEMENT, INC. This page lists 66 institutional shareholders reporting positions in this security for the Q4 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2023 vs Q3 2023 Across Filers

Q3 2023 holders

Q4 2023 holders

Holder diff

Investor	Q3 2023 Shares	Q4 2023 Shares	Share Diff	Share Chg %	Q3 2023 Value $	Q4 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.